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Safe drugs to ﬁght mutant protein overload and
alpha-1-antitrypsin deﬁciency
JOURNAL OF HEPATOLOGYTo the Editor:
We read with interest the commentary, ‘‘Drug enhanced autoph-
agy to ﬁght mutant protein overload’’, by Mehrpour and Codogno
[1]. The authors discuss recent experimental ﬁndings by Hidvegi
et al., in a in vitro and in an animal model of alpha-1-antitrypsin
(AT) deﬁciency, which raise the interesting possibility that the
iminostilbene derivative carbamazepine (CBZ) could be used
to treat this severe liver disease in humans [1,2]. The authors
correctly conclude that these ﬁndings have provided the ratio-
nale for studies on CBZ in patients with AT deﬁciency [1].
However, in our opinion, they overlooked that at least one cru-
cial, open question remains to be clariﬁed, before application of
these ﬁndings in clinical practice. This concerns the fact that in
the preclinical mouse model of AT deﬁciency, used for evaluat-
ing the CBZ effects, the results have been obtained with doses
of the drug signiﬁcantly higher than the doses used in humans
(200 mg/kg/day vs. 10–20 mg/kg/day), lower doses of CBZ have
not been effective, and in the study, the plasma levels of CBZ
have not been evaluated [1,2]. However, it is worth noting that
as stated by Hidvegi et al. in the discussion section of their
paper [2], ‘‘Effective doses of drugs can be 10- to 20-fold
higher in mice because of the higher ratio of surface area to
weight when compared to humans’’, and that the ﬁndings from
preclinical and clinical studies exempliﬁed in Table 1 ﬁt this
statement.
CBZ is a safe drug with a wide clinical spectrum of action
which ranges from epileptic seizures to cerebellar tremors and
myotonia [3–5], with well-known plasma therapeutic levels in
each of these pathologies [3–5]. In particular, an analysis of the
relationship between CBZ doses per body weight, necessary for
clinical effects and CBZ plasma levels, indicates that in humans
severe neurological and cardiovascular effects are usually seen
at CBZ daily doses higher than 20 mg/kg, and at plasma CBZ levels
greater than 12 lg/ml [6,7].Table 1
Oral doses and plasma therapeutic levels of carbamazepine in preclinical and clini
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Journal of Hepatology 20Oral doses and plasma therapeutic levels of CBZ in preclinical
and clinical studies are shown in Table 1. In preclinical studies,
oral doses of CBZ seem poor predictive of plasma concentrations
of the drug, likely due to the very different bioavailability of oral
CBZ preparations used in the different studies. Thus, in preclinical
studies, the determination of plasma CBZ concentrations seems
particularly advisable. In clinical studies, instead, some relation-
ship between oral doses of CBZ and therapeutic plasma levels
seems evident.
At present, the determination of plasma CBZ levels is a routi-
nary and rather easy task both in clinical and experimental set-
tings [3–5], and further studies on the therapeutic plasma
levels of CBZ in preclinical animal models of AT deﬁciency could
help to improve the quality of clinical trials aimed at assessing
the efﬁcacy of CBZ in patients with liver disease as a result of
AT deﬁciency.
Moreover, another relevant question the authors discussed
in the commentary is that the ﬁndings by Hidvegi et al. also
provide a proof of principle for therapeutic use of other safe
autophagy enhancer drugs, potentially useful to ﬁght protein
overload in different genetic diseases [1]. Interestingly, the b-
lactam antibiotic ceftriaxone, commonly used for decades in
patients with moderate to severe exacerbations of chronic
obstructive pulmonary disease related to AT deﬁciency [8],
was recently shown to also be able to eliminate the toxic
effects of misfolded glial ﬁbrillary acidic protein (GFAP) in a
cellular model of Alexander disease, a rare, usually fatal neuro-
degenerative disorder, by decreasing GFAP intracytoplasmic
aggregates, through complex biochemical mechanisms involv-
ing GFAP promoter down-regulation and enhancement of
autophagy [9,10]. The question is now whether ceftriaxone will
also be useful in treating other diseases caused by intracellular
accumulation and aggregation of misfolded proteins such as AT
deﬁciency.cal studies.
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liver disease: Pitfal
To the Editor:
Patients with liver disease frequently develop substantial
changes in their hemostatic system [1]. Recent laboratory and
clinical data are compatible with the concept of rebalanced
hemostasis in liver disease [2]. According to this concept, the
average patient with liver disease is in hemostatic balance due
to a concomitant decrease in pro- and anticoagulant pathways.
The hemostatic balance in patients with liver disease, however,
is much more fragile as compared to the hemostatic balance in
healthy individuals. Consequently, patients with liver disease
are at risk for both bleeding and thrombosis when the balance
is disturbed. Unfortunately, there is currently no clinical or labo-
ratory test able to predict whether a patient with liver disease is
at risk for either bleeding or thrombosis.
In a recent commentary in the section ‘‘International Hepatol-
ogy’’ of this Journal, Thabut and coworkers address the question
whether administration of recombinant factor VIIa (NovoSeven,
rFVIIa) to patients with liver disease poses them at an increased
risk for thrombotic complications [3]. The authors conclude that
the use of rFVIIa to patients with uncontrollable bleeding may be
justiﬁed, and potential thrombotic events should be considered
as ‘collateral damage’. Here, we aim to comment on the use of
rFVIIa in patients with liver disease to better appreciate the
risk-beneﬁt ratio in different clinical scenarios.
Current clinical data do not support prophylactic administra-
tion of rFVIIa to prevent excessive bleeding during surgical proce-
dures including partial hepatectomy and liver transplantation
[4,5]. Also, administration of rFVIIa to patients with variceal
bleeding is not indicated based on randomized controlled trials.
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ls and possibilities
Although the average patient with liver disease is in hemo-
static balance, there are situations in which severe and uncon-
trollable bleeding does occur [1]. If the primary cause of
bleeding is not surgical and not primarily related to (excessive)
portal hypertension, administration of rFVIIa may be beneﬁcial,
which is supported by anecdotal reports [6,7]. The main advan-
tage of rFVIIa over other hemostatic therapies, such as blood
product infusion, is the low volume, which prevents ﬂuid over-
load and exacerbation of portal hypertension. In addition, trans-
fusion-related complications such as transfusion-related acute
lung injury and other transfusion reactions do not occur when
rFVIIa is administered.
The theoretical advantages of rFVIIa when used as a ‘‘rescue
agent’’ need to be balanced against a potentially increased risk
of thrombosis. We believe that clinical studies are required to
establish whether rFVIIa is truly effective in controlling bleeding
complications in patients with liver disease. Furthermore, we
believe it is important to realise which types of uncontrollable
bleeding might beneﬁt from rFVIIa administration, and in which
cases therapy with rFVIIa is likely futile.
The patients with uncontrollable bleeding that may beneﬁt
from rFVIIa are those patients in whom the bleeding complica-
tion is likely a result of an inadequate coagulation system. Exam-
ples of this are patients with massive hematomas, patients with
bleeding complications after small invasive procedures including
dental extraction, liver biopsy, paracenthesis and thoracenthesis,
and patients with bleeding complications during or after larger
invasive procedures. In the latter case, it should be excluded that
there is a surgical cause for the bleeding complication. Clinically,
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